An ongoing phase III study is evaluating PEM plus ipilimumab versus PEM in NSCLC patients with PD‐L1 TPS of ≥50% (KEYNOTE‐598, NCT03302234), which will further provide answers for whether there is an added value of ipilimumab to PD‐1 blockade and whether there is a difference between nivolumab and PEM, when combined with ipilimumab. Here, PDCD1 is linked to non-small cell lung carcinoma.